HQ: Chicago, IL
Leadership: Jeffrey Aronin, Eric Messner
Website: emalexbiosciences.com
Opportunity: Develop and commercialize new treatments for rare and orphan neurological conditions.
Vision: Improve lives by providing novel treatments to patients with rare diseases that have limited or no treatment options.
Status: Active
> First partnered with Valor in 2018.
> Emalex is currently focused on developing ecopipam, a first-in-class drug being evaluated in pediatric patients for the treatment of Tourette’s Syndrome and for the treatment of Childhood-Onset Fluency Disorder (also known as “Stuttering”) in adults.
> As of January 2020, Emalex is conducting two Phase II clinical trials to further evaluate ecopipam’s efficacy and safety in patients with Tourette’s Syndrome and Stuttering.
> Emalex received FDA “Fast Track Designation” for ecopipam for the treatment of pediatric Tourette’s Syndrome. Ecopipam has additionally earned Orphan Drug Designation for Tourette’s Syndrome in the U.S.
